Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 3978-3981

  Cancilla, Mark T ^a   He, Molly M ^a   Viswanathan, Nina ^a   Simmons, Robert L ^a   Taylor, Meggin ^a   Fung, Amy D ^a   Cao, Kathy ^a   Erlanson, Daniel A ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Aurora; Cysteine; DCC; DFG out; Dynamic combinatorial chemistry; FBLD; Fragment based; Fragment based lead discovery; Kinase; Mass spectrometry; Site directed

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; CYSTEINE; DISULFIDE; LIGAND; PURINE;

ARTICLE; BINDING SITE; COMBINATORIAL CHEMISTRY; CONFORMATION; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; MASS SPECTROMETRY; REACTION ANALYSIS; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; SYNTHESIS;

BINDING SITES; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; LIGANDS; MASS SPECTROMETRY; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PROTEIN-SERINE-THREONINE KINASES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47149092363     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.011     Document Type: Article

References (30)

1. Lehn J.-L. Chemistry-A European Journal 5 (1999) 2455
2. Bunyapaiboonsri T., Ramstrom O., Lohmann S., Lehn J.M., Peng L., and Goeldner M. ChemBioChem 2 (2001) 438
3. Rowan S.J., Cantrill S.J., Cousins G.R.L., Sanders J.K.M., and Stoddart J.F. Angew. Chem., Int. Ed. 41 (2002) 898
4. Ramstrom O., and Lehn J.M. Nat. Rev. Drug Discov. 1 (2002) 26
5. Corbett P.T., Leclaire J., Vial L., West K.R., Wietor J.L., Sanders J.K., and Otto S. Chem. Rev. 106 (2006) 3652
6. Erlanson D.A., McDowell R.S., and O'Brien T. J. Med. Chem. 47 (2004) 3463
7. Rees D.C., Congreve M., Murray C.W., and Carr R. Nat. Rev. Drug Discov. 3 (2004) 660
8. Jahnke, W. Erlanson, D. A., Eds. Fragment-based Approaches in Drug Discovery. In Methods and Principles in Medicinal Chemistry; Mannhold, R.; Kubinyi, H.; Folkers, G., Series Eds.; Wiley-VCH: Weinheim, Germany, 2006; Vol. 34.
9. Erlanson D.A. Curr. Opin. Biotechnol. 17 (2006) 643
10. Hajduk P.J., and Greer J. Nat. Rev. Drug. Discov. 6 (2007) 211
11. Congreve M., Chessari G., Tisi D., and Woodhead A.J. J. Med. Chem. (2008) 10.1021/jm8000373
12. Huc I., and Lehn J.M. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2106
13. Hochgurtel M., Kroth H., Piecha D., Hofmann M.W., Nicolau C., Krause S., Schaaf O., Sonnenmoser G., and Eliseev A.V. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3382
14. Congreve M.S., Davis D.J., Devine L., Granata C., O'Reilly M., Wyatt P.G., and Jhoti H. Angew. Chem., Int. Ed. 42 (2003) 4479
15. Corbett A.D., Cheeseman J.D., Kazlauskas R.J., and Gleason J.L. Angew. Chem., Int. Ed. 43 (2004) 2432
16. Shi B., Stevenson R., Campopiano D.J., and Greaney M.F. J. Am. Chem. Soc. 128 (2006) 8459
17. Poulsen S.A., and Bornaghi L.F. Bioorg. Med. Chem. 14 (2006) 3275
18. Lienard B.M., Selevsek N., Oldham N.J., and Schofield C.J. ChemMedChem 2 (2007) 175
19. Lienard B.M., Huting R., Lassaux P., Galleni M., Frere J.M., and Schofield C.J. J. Med. Chem. 51 (2008) 684
20. Tethering is a registered service mark of Sunesis Pharmaceuticals, Inc., for its fragment-based drug discovery.
21. Erlanson D., Braisted A., Raphael D., Randal M., Stroud R., Gordon E., and Wells J. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9367
22. Erlanson D.A., Lam J.W., Wiesmann C., Luong T.N., Simmons R.L., DeLano W.L., Choong I.C., Burdett M.T., Flanagan W.M., Lee D., Gordon E.M., and O'Brien T. Nat. Biotechnol. 21 (2003) 308
23. Erlanson D.A., Wells J.A., and Braisted A.C. Annu. Rev. Biophys. Biomol. Struct. 33 (2004) 199
24. Keen N., and Taylor S. Nat. Rev. Cancer 4 (2004) 927
25. Elling R.A., Tangonan B.T., Penny D.M., Smith J.T., Vincent D.E., Hansen S.K., O'Brien T., and Romanowski M.J. Protein Expr. Purif. 54 (2007) 139
26. Bridges A.J. Chem. Rev. 101 (2001) 2541
27. Aurora A protein (Ref. 25, T217C) was adjusted to a final concentration of 5 μM in 50 mM Tris, pH 8, and 1 mM 2-mercaptoethanol. A 96-well plate format was used with a 40-μL total reaction volume per well. Each well contained the dynamic extender 1 at 50 μM, 10 unique disulfide containing fragments at 50 μM each, and the 5 μM protein/2-mercaptoethanol solution. After 4 h at room temperature each well was subjected to LC/MS analysis using a LCT time-of-flight mass spectrometer equipped with an eight-channel parallel multiplexed (MUX) ESI interface and (Waters Corp., Milford, MA) equipped with a Gilson 215/889 eight channel liquid handler (Gilson, Middleton, WI). The protein samples were desalted using reverse-phase Protein μTraps (Michrom BioResources Inc., Auburn CA) with a linear gradient of 5% acetonitrile (0.1% formic acid) to 95% acetonitrile (0.1% formic acid) over 0.3 min (held at 95% acetonitrile (0.1 % formic acid) for 2.3 min) at a total flow rate of 600 μL/min (75 μL/min per channel). Protein charge state distributions were deconvoluted to obtain the zero-charge spectrum using the MaxEnt algorithm (Waters Corp., Milford, MA).
28. Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., and Thompson D.A. Structure 10 (2002) 1659
29. Jung F.H., Pasquet G., Lambert-van der Brempt C., Lohmann J.J., Warin N., Renaud F., Germain H., De Savi C., Roberts N., Johnson T., Dousson C., Hill G.B., Mortlock A.A., Heron N., Wilkinson R.W., Wedge S.R., Heaton S.P., Odedra R., Keen N.J., Green S., Brown E., Thompson K., and Brightwell S. J. Med. Chem. 49 (2006) 955
30. DeLano, W. L. http://pymol.sourceforge.net/.